$285.75
Value $689B
JNJ and UNH stock compared: price, dividend, valuation and results, from SEC filings.
$285.75
Value $689B
$407.46
Value $370B
Johnson & Johnson (JNJ) has a market value of $689B and UnitedHealth (UNH) $370B. Over the last year, with dividends, JNJ moved +50.3% and UNH +23.4%. The P/E is 42.8 for JNJ and 23.3 for UNH. Dividend yield: JNJ 1.85%, UNH 2.22%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
JNJ$689B
UNH$370B
JNJ is 1.9 times UNH
Revenue, 12 months
JNJ$99.3B
UNH$450B
UNH is 4.5 times JNJ
Net income, 12 months
JNJ$16.1B
UNH$15.9B
About the same
Operating margin
JNJ–
UNH5.3%
ROIC
JNJ12.4%
UNH11.3%
1.1 points apart
P/E
JNJ42.8
UNH23.3
JNJ is 1.8 times UNH
Dividend yield
JNJ1.8%
UNH2.2%
0.3 points apart
5-year return
JNJ+99.1%
UNH-2.8%
101.9 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
JNJ+99.1%
UNH-2.8%
| Period | JNJWith dividends | UNHWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | +50.3%Price +47.0% | +23.4%Price +20.2% |
| 3 years since November 13, 2023 | +110.8%+28.2% a yearPrice +93.6% | -20.0%-7.2% a yearPrice -24.9% |
| 5 years since November 12, 2021 | +99.1%+14.8% a yearPrice +73.2% | -2.8%-0.6% a yearPrice -11.2% |
| 10 years since November 14, 2016 | +221.6%+12.4% a yearPrice +145.1% | +215.9%+12.2% a yearPrice +167.6% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
JNJJohnson & JohnsonUNHUnitedHealth
| Price | $285.75 | $407.46 |
|---|---|---|
| Market value | $689B | $370B |
| Enterprise value (EV) | $716B | $416B |
| P/E | 42.8 | 23.3 |
| P/E, 5-year median | 21.9 | 25.0 |
| P/B | 8.5 | 3.6 |
| EV/EBIT | 40.4 | 17.4 |
| Free cash flow yield | 3.0% | 6.2% |
| Revenue, 12 months | $99.3B | $450B |
|---|---|---|
| Net income, 12 months | $16.1B | $15.9B |
| Free cash flow, 12 months | $20.6B | $22.8B |
| Earnings per share, 12 months | $6.59 | $17.52 |
| Revenue growth, year on year | 6.1% | 11.8% |
| Revenue growth a year, past | +2.7%over 5 years | +11.7%over 5 years |
| EPS growth a year, past | +14.9%over 5 years | -3.8%over 5 years |
| Gross margin | 67.6% | 88.3% |
|---|---|---|
| Operating margin | – | 5.3% |
| Net margin | 16.2% | 3.5% |
| ROIC | 12.4% | 11.3% |
| ROE | 19.7% | 15.5% |
| Cash | $17.2B | $28.5B |
|---|---|---|
| Total debt | $44.7B | $74.3B |
| Net debt / EBITDA | 1.1 | 1.6 |
| Interest cover | 18.0× | 6.2× |
| Dividend yield | 1.8% | 2.2% |
|---|---|---|
| Dividend per share, 12 months | $5.28 | $9.06 |
| Dividend growth a year, past | +5.3%over 5 years | +12.6%over 5 years |
| Buyback yield | 0.9% | 1.5% |
| Shareholder yield | 2.7% | 3.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($689B) is about 1.9 times UnitedHealth ($370B), at today's prices.
Since November 14, 2016, JNJ's price moved +145.1% and UNH's +167.6%. With dividends: JNJ +221.6% (+12.4% a year), UNH +215.9% (+12.2% a year). Past returns do not predict future ones.
The dividend yield at today's price is 1.85% for Johnson & Johnson and 2.22% for UnitedHealth. Over the last twelve months they paid $5.28 and $9.06 per share.
At today's price, the P/E is 42.8 for JNJ and 23.3 for UNH. The median of the last five years was 21.9 and 25.0, which shows where each stands against its own past.
Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and 3.5% for UnitedHealth, and the operating margin – and 5.3%. Revenue was $99.3B and $450B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.